Amgen's Conundrum

Amgen (NASDAQ: AMGN  ) is in a bit of a conundrum.

The big biotech's talimogene laherparepvec -- T-VEC for short -- passed its primary endpoint, lowering the durable response rate in melanoma patients. But a secondary endpoint of overall survival just missed being statistically significant, with a p-value of 0.051. The Food and Drug Administration typically likes to see a p-value of less than 0.05, which equates to less than a 5% chance that the observed difference was due to chance alone.

In the following video, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss Amgen's chances for success, whether it will be able to compete with Bristol-Myers Squibb's (NYSE: BMY  ) Yervoy, and its potential to be used in combination with Yervoy and Merck's (NYSE: MRK  ) anti-PD-1 antibody MK-3475.

No conundrum here, these industries should have megagrowth
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2915021, ~/Articles/ArticleHandler.aspx, 9/4/2015 1:00:15 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated Moments ago Sponsored by:
DOW 16,078.45 -296.31 -1.81%
S&P 500 1,919.83 -31.30 -1.60%
NASD 4,676.64 -56.86 -1.20%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 12:44 PM
AMGN $146.42 Down -2.81 -1.88%
Amgen CAPS Rating: ****
BMY $57.52 Down -1.23 -2.09%
Bristol-Myers Squi… CAPS Rating: ****
MRK $51.33 Down -1.32 -2.51%
Merck & Co., Inc. CAPS Rating: ****